Resverlogix Corp.
TSX : RVX

Resverlogix Corp.

December 05, 2006 14:20 ET

Resverlogix Corp.: RVX208 Unique MOA Positions it as a Leader in ApoA-I/HDL Marketplace

Hundreds of thousands of patients in key landmark trials demonstrate that enhanced ApoA-I significantly reduces cardiovascular disease risk

CALGARY, ALBERTA--(CCNMatthews - Dec. 5, 2006) - Resverlogix Corp. ("Resverlogix") (TSX:RVX), announced that the Company's lead drug candidate RVX208 unique mechanism of action (MOA) is well positioned in the emerging HDL therapeutic market segment for reducing atherosclerosis and heart disease. Given recent events in the marketplace regarding cholesterol management drugs, Resverlogix verifies that its lead candidate will be tested in humans Q1 2007. It is imperative to understand that one of the most important factors for a successful drug target is to have large bodies of clinical evidence to support it, which Resverlogix does. More than 200,000 subjects have participated in the landmark Esperion trial and other major epidemiology trials such as AMORIS and INTERHEART. These clinical studies have built a very compelling body of evidence that ApoA-I, not other targets such as CETP or PPAR, has the most robust clinical validation demonstrating a reduction in cardiovascular disease risk.

"As confirmed in epidemiological and mechanistic studies and expressed at our Clinical Advisory Board meeting in November at the American Heart meeting in Chicago, increasing ApoA-I production is undoubtedly associated with CVD protection," said Dr. Jan Johansson, M.D., Ph.D., SVP Clinical Affairs, Resverlogix. "Resverlogix is in the unique position of having a small molecule drug that in animal studies increases the natural synthesis of ApoA-I. The enhancement of ApoA-I by RVX208 has the potential to become a first in class therapeutic for the treatment of atherosclerosis and cardiovascular disease," said Dr. Johansson.

Mr. Donald McCaffrey, President & CEO, Resverlogix stated, "Resverlogix's repeated success in the rapid onset of ApoA-I production is pointing to a definite pattern of predictability in our data. This intriguing pattern will likely provide Resverlogix with multiple opportunities in the marketplace including acute, chronic and combination therapies thus permitting us to treat patients across several categories."

Additionally Dr. Johansson stated, "As a point of clarification, there is no known link between ApoA-I metabolism per se and blood pressure. Epidemiological data consistently demonstrates that subjects who have a high plasma ApoA-I concentration also have low-normal blood pressure. Presently it is not known if the lower blood pressure in subjects with high ApoA-I is because of their cleaner and less atherosclerotic blood vessels or because of hereditary and/or life style reasons."

In the United States one person will die every 30 seconds from cardiovascular disease, the leading cause of death in the Western world. CVD can be generally defined as any abnormal condition characterized by dysfunction of the heart and blood vessels. CVD includes atherosclerosis (especially coronary heart disease which can lead to heart attacks), cerebrovascular disease (stroke), and hypertension (high blood pressure). The underlying cause of most CVD is a gradual clogging of the arteries (atherosclerosis) that supply blood to the heart, brain and other vital organs.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company in the development of novel therapies for important global medical markets with significant unmet medical needs. The Company's primary focus is to conduct leading research, development and commercialization of novel therapeutics that address the risk of Cardiovascular Disease (CVD). Through successful research efforts, the Company has expanded its CVD platform to three programs, each addressing different targets for specific commercial markets. NexVas™ Plaque Reduction (NexVas PR), is the Company's primary program that targets ApoA-I enhancement via novel small molecules for plaque stabilization and regression. NexVas™ Vascular Inflammation (NexVas VI) is the Company's second CVD program, a discovery stage technology focused on molecular targets of vascular inflammation. ReVas™ the Company's third CVD program is dedicated to the research and development of therapeutic compounds to be used with medical devices and biomaterials for the local non-systemic treatment of CVD, in particular restenosis. The Company has partnered ReVas™ with Medtronic Inc., a world leading medical technology company. The Company's secondary focus is TGF-Beta Shield™, a program that aims to address the unmet medical needs of burgeoning grievous diseases, such as cancer and fibrosis, with a TGF- Beta inhibitor. Resverlogix is committed to applying the qualities of innovation, integrity and sound business principles in developing novel therapies for the treatment of unmet human diseases. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information, please visit our web site at www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

Contact Information

  • Resverlogix Corp.
    Kenneth Lebioda
    Senior Vice President, Business & Market Development
    (403) 254-9252 ext. 227
    (403) 256-8495 (FAX)
    Email: ken@resverlogix.com
    or
    Resverlogix Corp.
    Theresa Kennedy
    Vice President, Corporate Communications
    (604) 538-7072
    (403) 256-8495 (FAX)
    Email: Theresa@resverlogix.com
    Website: www.resverlogix.com